請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29494完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳明汝(Ming-Ju Chen) | |
| dc.contributor.author | Jen-Yuan Chen | en |
| dc.contributor.author | 陳振元 | zh_TW |
| dc.date.accessioned | 2021-06-13T01:08:33Z | - |
| dc.date.available | 2010-07-30 | |
| dc.date.copyright | 2007-07-30 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-19 | |
| dc.identifier.citation | 中國國家標準。1984。食品中粗灰分之檢驗方法,CNS 5034。經濟部標準檢驗局,臺北。
中國國家標準。1984。食品中粗脂肪之檢驗方法,CNS 5036。經濟部標準檢驗局,臺北。 中國國家標準。1991。食品微生物之檢驗法-生菌數之檢驗,CNS 10890。經濟部標準檢驗局,臺北。 中國國家標準。1998。食品微生物之檢驗法-大腸桿菌群之檢驗,CNS 10984。經濟部標準檢驗局,臺北。 中國國家標準。2003。乳品檢驗法-乳酸菌之檢驗,CNS 14760。經濟部標準檢驗局,臺北。 中國國家標準。2007。乳品檢驗法-水分之測定,CNS 3443。經濟部標準檢驗局,臺北。 中國國家標準。2007。乳品檢驗法-蛋白質之測定,CNS 3449。經濟部標準檢驗局,臺北。 中國國家標準。2007。乳品檢驗法-酸度之測定,CNS 3441。經濟部標準檢驗局,臺北。 毛漢梅。2002。以遺傳演算法探討酸凝酪中原生菌生長速率之最適化。國立臺灣大學畜產學研究所。臺北市。 邱欣怡。2004。藉最適化方法探討添加益菌質於囊壁材質對微膠囊化原生菌之影響。碩士論文。國立臺灣大學畜產學研究所。臺北市。 周佳蓉。2003。藉由遺傳演算法與序列二次規劃法探討原生菌奶豆腐最佳製作條件。國立臺灣大學畜產學研究所。臺北市。 翁瑋蓮。1999。以反應曲面法探討扣碗酪之最佳生產模式。碩士論文。國立臺灣大學畜產學研究所。臺北市。 郭怡孜。2006。應用最適化方法開發具隔熱性益生菌微膠囊。碩士論文。國立臺灣大學動物科學技術學研究所。臺北市。 許佳憲。2006。應用序列二次規劃法開發益生菌乳錠。碩士論文。國立臺灣大學動物科學技術學研究所。臺北市。 蒲孝如。2006。柵欄技術應用於桃園大溪地區豆腐乾衛生品質之改善。國立臺灣大學食品科技研究所。臺北市。 賴仲豪。2006。應用最適化方法開發機能性發酵乳油。碩士論文。國立臺灣大學動物科學技術學研究所。臺北市。 Ames, B. N. and J. Liu. 2004. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann. N.Y. Acad. Sci. 1033: 108-116. Arduini, A., N. Denisova, M. A. Virmani, N. Avrova, G. Federici, and E. Arrigoni-Martelli. 1994. Evidence for the involvement of carnitine-dependent long-chain acyltransferases in neuronal triacylglycerol and phospholipid fatty acid turnover. J. Neurochem. 62: 1530-1538. Arrigoni-Martelli, E. and V. Caso. 2001. Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp. Clin. Res. 27: 27-49. Benvenga, S., A. Amato, M. Calvani, and F. Trimarchi. 2004. Effects of carnitine on thyroid hormone action. Ann. N.Y. Acad. Sci. 1033: 158-167. Binienda, Z., B. Przybyla-Zawislak, A. Virmani, and L. Schmued. 2005. L-carnitine and neuroprotection in the animal model of mitochondrial dysfunction. Ann. N.Y. Acad. Sci. 1053: 174-182. Box, G. E. P. and D. W. Behnken. 1960. Some new three level designs for the study of quantitative variables. Technometrics 2: 455-475. Bremer, J. 1983. Carnitine-metabolism and functions. Physiol. Rev. 63: 1420-1480. Brooks, J. O., J. A. Yesavage, A. Carta, and D. Bravi. 1998. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int. Psychogeriatr. 10: 193-203. Cacciatore, L., R. Cerio, M. Ciarimboli, M. Cocozza, V. Coto, A. D'Alessandro, L. D'Alessandro, G. Grattarola, L. Imparato, and M. Lingetti. 1991. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp. Clin. Res. 17: 225-235. Calvani, M., P. Benatti, A. Mancinelli, S. D’Iddio, V. Giordano, A. Koverech, A. Amato, and E. P. Brass. 2004. Carnitine replacement in end-stage renal disease and hemodialysis. Ann. N.Y. Acad. Sci. 1033: 52-66. Carter, A. L., T. O. Abney, and D. F. Lapp. 1995. Biosynthesis and metabolism of carnitine. J. Child Neurol. 10: S3-S7. Chen, K. N., M. J. Chen, and C. W. Lin. 2006. Optimal combination of the encapsulating materials for probiotic microcapsules and its experimental verification (R1). J. Food Eng. 76: 313-320. Chen, M. J., K. N. Chen, and C. W. Lin. 2004a. Sequential quadratic programming for development of a new probiotic dairy tofu with glucono-δ-lactone. J. Food Sci. 69: 344-350. Chen, M. J., K. N. Chen, and C. W. Lin. 2004b. Optimization of the viability of probiotics in a fermented milk drink by the response surface model. Asian-Aust. J. Anim. Sci. 17: 705-711. Chen, M. J., K. N. Chen, and C. W. Lin. 2005. Optimization of incorporated prebiotics as coating materials for probiotic microencapsulation. J. Food Sci. 70: 260-267. Costell, M., J. E. O'Connor, and S. Grisolia. 1989. Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem. Biophys. Res. Commun. 161: 1135-1143. Cruciani, R. A., E. Dvorkin, P. Homel, B. Culliney, S. Malamud, L. Shaiova, S. Fleishman, J. Lapin, E. Klein, P. Lesage, R. Portenoy, and N. Esteban-Cruciani. 2004. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency. A preliminary analysis. Ann. N.Y. Acad. Sci. 1033: 168-176. Dave, R. I. and N. P. Shah. 1998. Ingredient supplementation effects on viability of probiotic bacteria in yogurt. J. Dairy Sci. 81: 2804-2816. Davini, P., A. Bigalli, F. Lamanna, and A. Boem. 1992. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp. Clin. Res. 18: 355-365. Day, L., C. Shikuma, and M. Gerschenson. 2004. Acetyl-L-carnitine for the treatment of HIV lipoatrophy. Ann. N.Y. Acad. Sci. 1033: 139-146. Demarquoy, J., B. Georges, C. Rigault, M. Royer, A. Clairet, M. Soty, S. Lekounoungou, and F. L. Borgne. 2004. Radioisotopic determination of L-carnitine content in foods commonly eaten in Western countries. Food Chem. 86: 137-142. Duran, M., N. E. Loof, D. Ketting, and L. Dorland. 1990. Secondary carnitine deficiency. J. Clin. Chem. Clin. Biochem. 28: 359-363. Famularo, G., C. D. Simone, V. Trinchieri, and L. Mosca. 2004. Carnitines and its congeners: A metabolic pathway to the regulation of immune response and inflammation. Ann. N.Y. Acad. Sci. 1033: 132-138. Ferrari, R., E. Merli, G. Cicchttelli, D. Mele, A. Fucili, and C. Ceconi. 2004. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann. N.Y. Acad. Sci. 1033: 79-91. Fooks, L. J., R. Fuller, and G. R. Gibson. 1999. Prebiotics, probiotics, and human gut microbiology. Int. Dairy J. 9: 53-61. Gregory, M. J. and G. J. Schwartz. 1998. Diagnosis and treatment of renal tubular disorders. Semin. Nephrol. 18: 317-329. Gill, P. E., W. Murrary, and M. H. Wright. 1989. Practical optimization, 8th ed. Acadmic Press, San Diego, California. Giovanni, M. 1983. Response surface methodology and product optimization. Food Technol. 37: 41-45. Hagen, T. M., J. Liu, J. Lykkesfeldt, C. M. Wehr, R. T. Ingersoll, V. Vinarsky, J. C. Bartholomew, and B. N. Ames. 2002. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc. Natl. Acad. Sci. USA. 99: 1870-1875. Hayakawa, K., J. Mizutani, K. Wada, T. Masai, I. Yoshihara, and T. Mitsuoka. 1990. Effects of soybean oligosaccharides on human faecal flora. Microb. Ecol. Health Dis. 3: 293-303. Hendler, S. S. and D. R. Rorvik. 2001. PDR for Nutritional Supplements. Montvale: Medical Economics Company, Inc. Hiatt, W. R. 2004. Carnitine and peripheral arterial disease. Ann. N.Y. Acad. Sci. 1033: 92-98. Indyk, H. E. and D. C. Woollard. 1995. Enzymatic determination of free carnitine in milk and infant formulas. J. AOAC Int. 78: 69-74. Jakobs, B. S. and R. J. Wanders. 1995. Fatty acid β-oxidation in peroxisomes and mitochondria: the first, unequivocal evidence for the involvement of carnitine in shuttling propionyl-CoA from peroxisomes to mitochondria. Biochem. Biophys. Res. Commun. 213: 1035-1041. Janer, C., C. Peláez, and T. Requena. 2004. Caseinomacropeptide and whey protein concentrate enhance Bifidobacterium lactis growth in milk. Food Chem. 86: 263-267. Jeulin, C. and L. M. Lewin. 1996. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum. Reprod. Update 2: 87-102. Jung, H., K. jung, and H. P. Klebar. 1993. Synthesis of L-carnitine by microorganisms and isolated enzymes. Adv. Biochem. Eng. Biotechnol. 50: 21-44. Kashiwagi, A., T. Kanno, K. Arita, R. Ishisaka, T. Utsumi, and K. Utsumi. 2001. Suppression of T(3)-and fatty acid-induced membrane permeability transition by L-carnitine. Comp. Biochem. Physiol. B: Biochem. Mol. Biol. 130: 411-418. Kelly, G. S. 1998. L-carnitine: therapeutic applications of a conditionally-essential amino acid. Altern. Med. Rev. 3: 345-360. Kenneth, R. 1990. Compositional elements affecting flavor of cultured dairy foods. J. Dairy Sci. 73: 3651-3656. Kerner, J. and C. Hoppel. 1998. Genetic disorders of carnitine metabolism and their nutritional management. Annu. Rev. Nutr. 18: 179-206. Kets, E. P. W. and J. A. M. de Bont. 1997. Effect of carnitines on Lactobacillus plantarum subjected to osmotic stress. FEMS Microbiol. Lett. 146: 205-209. Kleber, H. 1997. Bacterial carnitine metabolism. FEMS Microbiol. Lett. 147: 1-9. Kneifel, W., D. Jaros, and F. Erhard. 1993. Microflora and acidification properties of yoghurt and yoghurt-related products fermented with commercial available starter culture. Int. J. Food Microbiol. 18: 179-189. Kohmoto, T., F. Fukui, H. Takaku, Y. Machida, M. Arai, and T. Mitsuoka. 1988. Effect of isomalto-oligosaccharides on human fecal flora. Bifidobacteria Microflora 7: 61-69. Kroger, M. 1975. Quality of yogurt. J. Dairy Sci. 59: 344-350. Kumaran, S., K. S. Panneerselvam, S. Shila, K. Sivarajan, and C. Panneerselvam. 2005a. Age-associated deficit of mitochondrial oxidative phosphorylation in skeletal muscle: role of carnitine and lipoic acid. Mol. Cell Biochem. 280: 83-89. Kumaran, S., M. Subathra, M. Balu, and C. Panneerselvam. 2005b. Supplementation of L-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats. Exp. Aging Res. 31: 55-67. Lee, E. G., I. Y. Lee, and Y. H. Park. 1999. Microbial transformation of γ-butyrobetaine into L-carnitine by Achromobacter cytoclast. Korean J. Biotechnol. Bioeng. 14: 1-7. Liu, J., E. Head, A. M. Gharib, W. Yuan, R. T. Ingersoll, T. M. Hagen, C. W. Cotman, and B. N. Ames. 2002. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-α-lipoic acid. Proc. Natl. Acad. Sci. USA. 99: 2356-2361. Liu, J., E. Head, H. Kuratsune, C. W. Cotman, and B. N. Ames. 2004. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann. N.Y. Acad. Sci. 1033: 117-131. Lopaschuk, G. 2000. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am. Heart. J. 139: S115-119. Luenberger, D. G. 1984. Linear and nonlinear programming. Addison-Wesley Publishing Company, Reading, M. A. Macedo, R. F., J. S. R. Freitas, A. Pandey, and C. R. Soccol. 1999. Production and shelf-life studies of low cost beverage with soymilk, buffalo cheese whey and cow milk fermented by mixed cultures of Lactobacillus casei ssp. shirota and Bifidobacterium adolescentis. J. Basic Microbiol. 39: 243-251. Manoli, I., M. U. De Martino, T. Kino, and S. Alesci. 2004. Modulatory effects of L-carnitine on glucocorticoid receptor activity. Ann. N.Y. Acad. Sci. 1033: 147-157. Martín-Diana, A. B., C. Janer, C. Peláez, and T. Requena. 2003. Development of a fermented goat’s milk containing probiotic bacteria. Int. Dairy J. 13: 827-833. Mattila-Sandholm, T., P. Myllarinen, R. Crittenden, G. Mogensen, R. Fonden, and M. Saarela. 2002. Technological challenges for future probiotic foods. Int. Dairy J. 12: 173-182. McGarry, J. D. and N. F. Brown. 1997. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244: 1-14. McGrane, M. M. 2000. Carbohydrate metabolism--synthesis and oxidation. In: Stipanuk, M. H., ed. Biochemical and Physiological Aspects of Human Nutrition. Philadelphia: W.B. Saunders Co. 158-210. Medina, L. M. and R. Jordano. 1994. Survival of constitutive microflora in commercially fermented milk containing bifidobacteria during refrigerated storage. J. Food Prot. 56: 731-733. Mills, J. L. 2002. Peripheral arterial disease. In: Rakel, R. E. and E. T. Bope, eds. Conn's Current Therapy. 54th ed. New York: W. B. Sunders Company. 340-343. Mingrone, G. 2004. Carnitine in type 2 diabetes. Ann. N.Y. Acad. Sci. 1033: 99-107. Moretti, S., G. Famularo, S. Marcellini, A. Boschini, G. Santini, V. Trinchieri, L. Lucci, E. Alesse, and C. De Simone. 2002. L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. Antioxid Redox Signal. 4: 391-403. Muthuswamy, A. D., K. Vedagiri, M. Ganesan, and P. Chinnakannu. 2006. Oxidative stress-mediated macromolecular damage and dwindle in antioxidant status in aged rat brain regions: role of L-carnitine and DL-alpha-lipoic acid. Clin. Chim. Acta. 368: 84-92. Naidu, G. S. N., I. Y. Lee, O. K. Cho, and Y. H. Park. 2001. Conversion of γ-butyrobetaine to L-carnitine by Achromobacter cycloclast. J. Ind. Microbiol. Biotechnol. 26: 309-315. Nezu, J., I. Tamai, A. Oku, R. Ohashi, H. Yabuuchi, N. Hashimoto, H. Nikaido, Y. Sai, A. Koizumi, Y. Shoji, G. Takada, T. Matsuishi, M. Yoshino, H. Kato, T. Ohura, G. Tsujimoto, J. Hayakawa, M. Shimane1, and A. Tsuji. 1999. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 21: 91-94. Ng, C. M., M. R. Blackman, C. Wang, and R. S. Swerdloff. 2004. The role of carnitine in the male reproductive system. Ann. N.Y. Acad. Sci. 1033: 177-188. Osio, M., F. Muscia, L. Zampini, C. Nascimbene, E. Mailland, A. Cargnel, and C. Mariani. 2006. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J. Peripher. Nerv. Syst. 11: 72-76. Pons, R. and D. V. Dc. 1995. Primary and secondary carnitine deficiency syndromes. J Child Neurol. 10: S8-24. Ramsay, R. R., R. D. Gandour, and F. R. van der leij. 2001. Molecular enzymology of carnitine transfer and transport. Biochim. Biophys. Acta. 1546: 21-43. Raymond, H. M. and C. M. Douglas. 1995. Response surface methodology: Process and product optimization using designed experiments. New York: John Wiley & Sons. Rebouche, C. J. 1996. Role of carnitine biosynthesis and renal conservation of carnitine in genetic and acquired disorders of carnitine metabolism. In: Seim, H. and H. Loster, eds. carnitine: pathobiochemical basics and clinical applications. Ponte Press, Bochum. 111-121. Rebouche, C. J. 2004. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann. N.Y. Acad. Sci. 1033: 30-41. Rebouche, C. J. 2006. Carnitine. In: Shils, M. E., M. Shike, A. C. Ross, B. Caballero, and R. J. Cousins, eds. Modern nutrition in health and disease. 10th ed. Philadelphia: Lippincott, Williams & Wilkins. 537-544. Rebouche, C. J. and H. Seim. 1998. Carnitine metabolism and its regulation in microorganisms and mammals. Annu. Rev. Nutr. 18: 39-61. Rizos, I. 2000. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am. Heart J. 139: S120-123. Sako, T., K. Matsumoto, and R. Tanaka. 1999. Recent progress on research and applications of non-digestible galato-oligosaccarides. Int. Dairy J. 9: 69-80. Savitha, S. and C. Panneerselvam. 2006. Mitochondrial membrane damage during aging process in rat heart: potential efficacy of L-carnitine and DL alpha lipoic acid. Mech. Aging Dev. 127: 349-355. Savitha, S., K. Sivarajan, D. Haripriya, V. Kokilavani, and C. Panneerselvam. 2005. Efficacy of levo carnitine and alpha lipoic acid in ameliorating the decline in mitochondrial enzymes during aging. Clin. Nutr. 24: 794-800. Scarpini, E., G. Sacilotto, P. Baron, M. Cusini, and G. Scarlato. 1997. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J. Peripher. Nerv. Syst. 2: 250-252. Seim, H., K. Eichler, and H. Kleber. 2001. L(-)-carnitine and its precursor, gamma-butyrobetaine. In: Kramer, K., P. Hoppe, and L. Packer, eds. Nutraceuticals in health and disease prevention. New York: Marcel Dekker, Inc. 217-256. Sethumadhavan, S. and P. Chinnakannu. 2006. L-carnitine and alpha-lipoic acid improve age-associated decline in mitochondrial respiratory chain activity of rat heart muscle. J. Gerontol. A. Biol. Sci. Med. Sci. 61: 650-659. Shankar, S. S., B. Mirzamohammadi, J. P. Walsh, and H. O. Steinberg. 2004. L-carnitine may attenuate free fatty acid–induced endothelial dysfunction. Ann. N.Y. Acad. Sci. 1033: 189-197. Spellucci, P. 1998. An SQP method for general nonlinear programs using only equality constrained subproblems. Mathematical Programing 82: 413-448. Stanley, C. A. 2004. Carnitine deficiency disorders in children. Ann. N.Y. Acad. Sci. 1033: 42-51. Thal, L. J., A. Carta, W. R. Clarke, S. H. Ferris, R. P. Friedland, R. C. Petersen, J. W. Pettegrew, E. Pfeiffer, M. A. Raskind, M. Sano, M. H. Tuszynski, and R. F. Woolson. 1996. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 47: 705-711. Vaz, F. M. and R. J. A. Wanders. 2002. Carnitine biosynthesis in mammals. Biochem. J. 361: 417-429. Verhoeven, N. M., D. S. Roe, R. M. Kok, R. J. Wanders, C. Jakobs, and C. R. Roe. 1998. Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts. J. Lipid. Res. 39: 66–74. Virmani, A. and Z. Binienda. 2004. Role of carnitine esters in brain neuropathology. Mol. Aspects Med. 25: 533-549. Virmani, A., F. Gaetani, S. Imam, Z. Binienda, and S. Ali. 2002. The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann. N.Y. Acad. Sci. 965: 225-232. Virmani, A., F. Gaetani, S. Imam, Z. Binienda, and S. Ali. 2003. Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity. Ann. N.Y. Acad. Sci. 993: 197-207. Virmani, M. A., V. Caso, A. Spadoni, S. Rossi, F. Russo, and F. Gaetani. 2001. The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurons. Ann. N.Y. Acad. Sci. 939: 162-178. Wang, Y., F. Taroni, B. Garavaglia, and N. Longo. 2000. Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype correlation. Hum. Mutat. 16: 401-407. Wang, Y., J. Ye, V. Ganapathy, and N. Longo. 1999. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc. Natl. Acad. Sci. USA 96: 2356-2360. Winter, S. C., S. Szabo-Aczel, C. J. Curry, H. T. Hutchinson, R. Hogue, and A. Shug. 1987. Plasma carnitine deficiency. Clinical observations in 51 pediatric patients. Am. J. Dis. Child 141: 660-665. Woollard, D. C., H. E. Indyk, and G. A. Woollard. 1997. Enzymatic determination of carnitine in milk and infant formula. Food Chem. 59: 325-332. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29494 | - |
| dc.description.abstract | 本試驗的目的在探討脫脂還原乳添加益菌質(果寡醣和異麥芽寡醣)、乳清濃縮蛋白粉及益生菌(Lactococcus lactis subsp. cremoris, Lc. lactis subsp. lactis, Lactobacillus rhamnosus),於37 ℃發酵7小時後,對產品中左旋肉生僉含量與乳酸菌數的影響。藉著反應曲面法建立數學模式,配合序列二次規劃法的最佳化搜尋,找出機能性發酵乳的最佳配方。擬開發出一種含有益生菌與益菌質,且富含左旋肉生僉的新健康食品,使產品能商品化,增加乳製品多樣性,提供國人新選擇。
試驗中以果寡醣、異麥芽寡醣及乳清濃縮蛋白粉的添加濃度為變因,而以機能性發酵乳發酵7小時完成時的左旋肉生僉含量與乳酸菌數為反應性狀,以反應曲面法中Box and Behnken的三因子三階次試驗設計,共得17個實驗組,實驗結果以Design-Expert軟體建立最適方程式,再經由序列二次規劃法尋求果寡醣、異麥芽寡醣及乳清濃縮蛋白粉的最佳添加比例。 結果顯示添加益菌質可提高發酵乳中左旋肉生僉含量,其中又以果寡醣添加1.0 %、異麥芽寡醣3.0 %及不添加乳清濃縮蛋白粉,進行發酵7小時製成的機能性發酵乳有最佳左旋肉生僉含量與乳酸菌數。以此最佳配方製成的機能性發酵乳進行成分分析、官能品評試驗及儲存試驗。 機能性發酵乳的基本組成為水分87.36 %、蛋白質3.59 %、脂肪0.08 %、碳水化合物8.24 %、灰分0.73 %、pH值6.34及滴定酸度0.23 %。官能品評試驗是比較機能性發酵乳、市售發酵優酪乳及未發酵脫脂還原乳的質地、外觀、氣味及口感,結果顯示市售發酵優酪乳整體評分最佳,但機能性發酵乳是以脫脂還原乳為基質,僅添加對人體有益的乳酸菌與益菌質(果寡醣與異麥芽寡醣),無添加糖與安定劑等任何添加物,具有淡淡乳粉味與乳白帶微黃色的外觀,飲用口感有些微甘甜味,倘要上市成為架上產品,須在各項官能品評項目上作改進,使其更具市場競爭力。儲存試驗於機能性發酵乳剛製成時有最佳左旋肉生僉含量22.08 ± 1.36 mg/100 g sample;乳酸菌數於剛製成時有7.6 ± 0.0 log CFU/mL,會隨儲存時間先增加再減少,且經過4℃儲存1個月後,乳酸菌數仍保有107 CFU/mL以上。而在儲存期間測得的總生菌數與乳酸菌數相近,且大腸桿菌群檢驗呈現陰性,顯示機能性發酵乳於儲存期間無其他微生物污染繁殖。另外,在儲存期間pH值逐漸下降,而滴定酸度則漸次增加。當儲存2~3週可直接觀察外觀變化,開始有乳清分離與些許酸臭味,故2週內為最佳保存期限。 | zh_TW |
| dc.description.abstract | The objective of this research was to create a new synbiotic fermented milk with high L-carnitine and healthy benefits. The final aim was to increase the variety and choice of dairy products. In this study, skim milk was mixed with prebiotics (fructooligosaccharides, FOS and isomaltooligosaccharides, IMO) and whey protein concentrate. The mixture was then inoculated with probiotics (Lc. lactis subsp. cremoris, Lc. lactis subsp. lactis, and Lb. rhamnosus) and fermented at 37 ℃ for 7 hr. Moreover, the proportion of the prebiotics and whey protein concentrate was optimized using response surface methodology (RSM) to construct a surface model, with sequential quadratic programming (SQP) subsequently adopted to optimize the model and the processing conditions.
Optimization results demonstrated that addition of prebiotics increased the level of L-carnitine and lactic acid bacteria (LAB) counts in fermented milk with 1.0 % FOS and 3 % IMO. The verification experiment yielded a result close to the predicted values, with no significant difference(P>0.05). The components of the functional fermented milk were 87.36 % moisture, 3.59 % CP, 0.08 % fat, 8.24 % carbohydrate and 0.73% ash. And the pH value and titratable acidity was 6.34 and 0.23%, respectively. Although the sensory evaluation results indicated that the consumers, giving a score above 6.0, could accept this product, additional sweeteners and flavors might be needed for possible commercialization of this product. The storage results showed that LAB counts remained above 107 CFU/mL for samples stored for one month. On contrast, L-carnitine contents dropped during storage. And the standard plate counts were very close to LAB counts with no coliform bacteria, it indicated that there were no other microorganisms grew in the functional fermented milk during storage. Because the post acidification happened during storage, pH value dropped and titratable acidity increased. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T01:08:33Z (GMT). No. of bitstreams: 1 ntu-96-R92626015-1.pdf: 1528162 bytes, checksum: 409d4aac54c6ea4bc685a3a1c0b9444e (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 口試委員會審定書.....i
誌謝.....ii 中文摘要.....iii 英文摘要.....v 目錄.....vii 表目錄.....x 圖目錄.....xi 第一章 緒言.....1 第二章 文獻探討.....2 第一節 何謂左旋肉生僉.....2 第二節 左旋肉生僉的生理功能.....13 一、左旋肉生僉能將活化狀態的長鏈脂肪酸從細胞質運輸至粒腺體內,以利脂肪酸進行β-氧化作用產生能量.....13 二、左旋肉生僉藉著調控乙醯輔酶A/輔酶A比例,間接調控能量代謝.....14 三、左旋肉生僉與乙醯左旋肉生僉具有神經保護功用,減少有害物質危害粒腺體.....14 四、左旋肉生僉與乙醯左旋肉生僉影響細胞膜及其功能.....16 五、左旋肉生僉為糖皮質激素受體α的營養調控者.....16 第三節 左旋肉生僉與人類疾病.....20 一、左旋肉生僉與乙醯左旋肉生僉的營養補充及肉生僉缺乏介紹.....20 二、左旋肉生僉與乙醯左旋肉生僉對疾病的治療應用.....22 第四節 藉由反應曲面法與最佳化方法開發機能性乳製品.....30 一、機能性奶豆腐.....30 二、益生菌微膠囊.....31 三、高共軛亞麻油酸機能性乳油.....31 四、機能性乳錠.....32 第三章 材料與方法.....33 第一節 實驗材料.....33 一、供試菌株.....33 二、發酵基質.....33 三、培養基與培養液.....33 四、藥品.....34 五、儀器設備.....34 第二節 實驗方法.....36 一、菌株的保存及更新.....36 二、探討富含左旋肉生僉機能性發酵乳最佳化生產的試驗架構.....36 三、分析方法.....39 第四章 結果與討論.....48 第一節 菌種篩選.....48 一、鮮乳與發酵乳製品的左旋肉生僉含量.....48 二、台北組克弗爾純化菌株的左旋肉生僉含量.....48 三、商業益生菌株的篩選.....49 第二節 機能性發酵乳的最佳化製作.....53 一、決定添加物種類及其使用的上下限.....53 二、決定機能性發酵乳的最佳發酵時間.....54 三、反應曲面法試驗設計與模式契合度探討.....55 四、建立數學模式目標函數及最佳配方搜尋.....58 第三節 機能性發酵乳的基本組成分析及官能品評試驗.....71 一、機能性發酵乳的基本組成分析.....71 二、機能性發酵乳的官能品評試驗.....71 第四節 儲存試驗.....76 一、pH值與滴定酸度於儲存期間的變化.....76 二、左旋肉生僉含量與乳酸菌數於儲存期間的變化.....76 三、總生菌數與大腸桿菌群細菌於儲存期間的變化.....77 第五章 結論.....82 參考文獻.....84 作者小傳.....96 附表.....97 | |
| dc.language.iso | zh-TW | |
| dc.subject | 序列二次規劃法 | zh_TW |
| dc.subject | 左旋肉生僉 | zh_TW |
| dc.subject | 果寡醣 | zh_TW |
| dc.subject | 異麥芽寡醣 | zh_TW |
| dc.subject | 反應曲面法 | zh_TW |
| dc.subject | sequential quadratic programming | en |
| dc.subject | L-carnitine | en |
| dc.subject | fructooligosaccharides | en |
| dc.subject | isomaltooligosaccharides | en |
| dc.subject | response surface methodology | en |
| dc.title | 應用序列二次規劃法開發富含左旋肉生僉機能性發酵乳 | zh_TW |
| dc.title | Development of a functional fermented milk with L-carnitine using sequential quadratic programming | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林慶文,王政騰,郭卿雲,劉?睿 | |
| dc.subject.keyword | 左旋肉生僉,果寡醣,異麥芽寡醣,反應曲面法,序列二次規劃法, | zh_TW |
| dc.subject.keyword | L-carnitine,fructooligosaccharides,isomaltooligosaccharides,response surface methodology,sequential quadratic programming, | en |
| dc.relation.page | 95 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-23 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
| 顯示於系所單位: | 動物科學技術學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 1.49 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
